Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population

Context Jinlong capsule (JLC) is an animal-derived traditional Chinese medical preparation for advanced hepatocellular carcinoma (HCC). However, its clinical efficacy is still not well investigated. Objective This study summarizes the efficacy and safety of JLC combined with trans-arterial chemoembo...

Full description

Bibliographic Details
Main Authors: Shuzhao Jia, Ying Fu, Huimin Tao
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Pharmaceutical Biology
Subjects:
Online Access:http://dx.doi.org/10.1080/13880209.2020.1799040
id doaj-9066b53e2701492ca6309ef171c3f82e
record_format Article
spelling doaj-9066b53e2701492ca6309ef171c3f82e2021-05-06T15:44:47ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162020-01-0158177178410.1080/13880209.2020.17990401799040Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese populationShuzhao Jia0Ying Fu1Huimin Tao2Department of Hepatobiliary Surgery, Liaocheng People’s HospitalDepartment of Oncology, Liaocheng People’s HospitalDepartment of Gastroenterology, Liaocheng People’s HospitalContext Jinlong capsule (JLC) is an animal-derived traditional Chinese medical preparation for advanced hepatocellular carcinoma (HCC). However, its clinical efficacy is still not well investigated. Objective This study summarizes the efficacy and safety of JLC combined with trans-arterial chemoembolization (TACE) for patients with HCC. Methods The databases PubMed, Cochrane Library, Web of Science, EMBASE, Medline, China National Knowledge Infrastructure, Wanfang Database, Chinese Scientific Journal Database and Chinese Biological Medicine Database were systematically searched from the date of their inception until February 2020. Jinlong capsule, trans-arterial chemoembolization, and hepatocellular carcinoma were the key terms searched. Randomized controlled trials and high-quality prospective cohort trials comparing the combined use of JLC and TACE versus TACE for HCC were included. Data were pooled using random or fixed effect models depending on heterogeneity. Results Data from 19 articles with 1,725 HCC patients were analysed. Compared with TACE treatment alone, the combination of TACE and JLC significantly prolonged patients’ 6–36 month overall survival (p < 0.05), and markedly improved the overall response rate (RR = 1.37, 95% CI = 1.24–1.52, p < 0.00001) and disease control rate (RR = 1.11, 95% CI = 1.06–1.17, p < 0.0001) of patients. The liver function, quality of life, and immune function of patients were significantly improved; the partial adverse events related to TACE were also effectively relieved after the combination treatment. Conclusion This meta-analysis suggests that the combination of TACE and JLC is more effective in the treatment of HCC than treatment with TACE alone.http://dx.doi.org/10.1080/13880209.2020.1799040traditional chinese medicineefficacysafetyimmune functionsystematic review
collection DOAJ
language English
format Article
sources DOAJ
author Shuzhao Jia
Ying Fu
Huimin Tao
spellingShingle Shuzhao Jia
Ying Fu
Huimin Tao
Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population
Pharmaceutical Biology
traditional chinese medicine
efficacy
safety
immune function
systematic review
author_facet Shuzhao Jia
Ying Fu
Huimin Tao
author_sort Shuzhao Jia
title Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population
title_short Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population
title_full Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population
title_fullStr Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population
title_full_unstemmed Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population
title_sort trans-arterial chemoembolization combined with jinlong capsule for advanced hepatocellular carcinoma: a prisma-compliant meta-analysis in a chinese population
publisher Taylor & Francis Group
series Pharmaceutical Biology
issn 1388-0209
1744-5116
publishDate 2020-01-01
description Context Jinlong capsule (JLC) is an animal-derived traditional Chinese medical preparation for advanced hepatocellular carcinoma (HCC). However, its clinical efficacy is still not well investigated. Objective This study summarizes the efficacy and safety of JLC combined with trans-arterial chemoembolization (TACE) for patients with HCC. Methods The databases PubMed, Cochrane Library, Web of Science, EMBASE, Medline, China National Knowledge Infrastructure, Wanfang Database, Chinese Scientific Journal Database and Chinese Biological Medicine Database were systematically searched from the date of their inception until February 2020. Jinlong capsule, trans-arterial chemoembolization, and hepatocellular carcinoma were the key terms searched. Randomized controlled trials and high-quality prospective cohort trials comparing the combined use of JLC and TACE versus TACE for HCC were included. Data were pooled using random or fixed effect models depending on heterogeneity. Results Data from 19 articles with 1,725 HCC patients were analysed. Compared with TACE treatment alone, the combination of TACE and JLC significantly prolonged patients’ 6–36 month overall survival (p < 0.05), and markedly improved the overall response rate (RR = 1.37, 95% CI = 1.24–1.52, p < 0.00001) and disease control rate (RR = 1.11, 95% CI = 1.06–1.17, p < 0.0001) of patients. The liver function, quality of life, and immune function of patients were significantly improved; the partial adverse events related to TACE were also effectively relieved after the combination treatment. Conclusion This meta-analysis suggests that the combination of TACE and JLC is more effective in the treatment of HCC than treatment with TACE alone.
topic traditional chinese medicine
efficacy
safety
immune function
systematic review
url http://dx.doi.org/10.1080/13880209.2020.1799040
work_keys_str_mv AT shuzhaojia transarterialchemoembolizationcombinedwithjinlongcapsuleforadvancedhepatocellularcarcinomaaprismacompliantmetaanalysisinachinesepopulation
AT yingfu transarterialchemoembolizationcombinedwithjinlongcapsuleforadvancedhepatocellularcarcinomaaprismacompliantmetaanalysisinachinesepopulation
AT huimintao transarterialchemoembolizationcombinedwithjinlongcapsuleforadvancedhepatocellularcarcinomaaprismacompliantmetaanalysisinachinesepopulation
_version_ 1721456514025127936